Plug-shaped implant for the replacement and regeneration of biological tissue and method for preparing the implant - Patents.com
A plug-shaped implant with a non-biodegradable design addresses the challenge of osteochondral defects by regenerating cartilage and bone, offering durable repair and preventing osteoarthritis through improved load distribution and cartilage regeneration.
Patent Information
- Application Number
- JP2021576061
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-27
- Filing Date
- 2020-06-23
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-06-23
AI Technical Summary
Current treatments for osteochondral defects, such as joint replacement and bioregenerative therapies, fail to provide durable and effective cartilage regeneration, leading to osteoarthritis and the need for frequent surgical interventions.
A plug-shaped implant with a non-biodegradable design, featuring a thermoplastic elastomeric upper section and a biocompatible base zone, which includes materials like polyaryletherketone polymers, metals, and ceramics, to replace and regenerate cartilage and bone, respectively, promoting cartilage growth and integration.
The implant effectively regenerates cartilage, providing durable repair and preventing or postponing the need for artificial joint replacement by enhancing load distribution and cartilage regeneration, maintaining joint functionality over time.
Smart Images

Figure 0007584153000003 
Figure 0007584153000004 
Figure 0007584153000005
Abstract
Description
[Technical field]
[0001] The present invention relates to an implant in the form of a plug for the replacement and regeneration of living tissue. The present invention particularly relates to an implant in the form of a plug for the replacement and regeneration of osteochondral structures. The present invention further relates to a method for the preparation of the implant and to an osteochondral structure comprising the implant. [Background technology]
[0002] Osteochondral structures refer to structures that include cartilage and bone. Typical osteochondral structures can be found in the thighbone (femur), shinbone (tibia), and kneecap (patella). Such structures fit tightly and move smoothly because the bone surfaces are covered with a relatively thick layer of articular (hyaline) cartilage. An (osteochondral) defect is any type of damage to the articular cartilage and, optionally, the underlying (subchondral) bone. Usually, (osteochondral) defects appear in specific weight-bearing spots, for example, at the ends of the femur and tibia, and at the back of the kneecap. They can range from roughened cartilage, fragments of ossicles and cartilage that impede movement, to complete loss of cartilage.
[0003] Trauma to the articular surface is common in young active people practicing sports or as a sequela of accidents. The lesions may involve not only the cartilage layer but also, in many cases, the underlying subchondral bone. Articular cartilage has a very low tendency to heal and the repair tissue is qualitatively inferior to the original tissue. This always leads to the formation of osteoarthritis (OA) over the years, which is the main cause of disability and reduced quality of life in the elderly. The standard treatment for this condition is ultimately joint replacement with an artificial joint. Although clinically effective, non-biological implants do not last more than 10-20 years and revision surgery is much less effective and very costly. For this reason, much research has been dedicated to developing a lifelong lasting bioregenerative therapy. However, despite promising in vitro results, so far no single solution has proven to be more effective than the current standard of care over the long term in real life conditions.
[0004] Because the cartilage layer lacks nerve fibers, patients are often unaware of the severity of the damage. During the final stage, the affected joint consists of bone rubbing against bone, which leads to severe pain and limited mobility. By the time the patient seeks medical treatment, surgical intervention may be required to reduce pain and repair the cartilage damage. To avoid or postpone such surgical intervention, implants for joints have been developed. These can be implanted into the bone structure at the early stage of cartilage damage and thus provide for preventive treatment to avoid unnoticed degeneration of the joint.
[0005] Numerous therapies are available to treat articular cartilage damage in joints such as the knee, ranging from the most conservative and non-invasive options to total joint replacement if the damage has spread throughout the joint. Currently available treatments include anti-inflammatory drugs in the early stages. These can relieve pain, but have limited effect on arthritic symptoms and do not repair the joint tissue further. Cartilage repair methods such as arthroscopic debridement are attempted to at least slow the tissue degeneration. However, these methods are only partially effective in repairing the soft tissue and do not restore joint spacing or improve joint stability. Joint replacement (arthroplasty) is considered the final solution when all other options to relieve pain and restore mobility have not worked or are no longer effective. Although arthroplasty of the joint can be effective, the procedure is extremely invasive and technically challenging, which may impair future treatment options. Cartilage regeneration has also been attempted, more particularly by tissue engineering techniques. The use of cells, genes, and growth factors in combination with scaffolds plays a fundamental role in the regeneration of functional and viable articular cartilage. All these approaches are based on stimulating the body's normal healing or repair processes at the cellular level. Many of these compounds are delivered in a variety of carriers or matrices, including fibrous polylactic acid-based polymers or collagen fibers. Despite various attempts to regenerate cartilage, there is currently no reliable and proven treatment for repairing articular cartilage defects.
[0006] Another standard treatment is for small lesions (≤2cm 2 ), and larger lesions (>2cm 2 For the first two procedures, the first consists of the Autologous Chondrocyte Implantation (ACI). However, the cartilage tissue regenerated by these techniques cannot withstand the biomechanical challenges within the joint and begins to degenerate already within 18 months. Therefore, a substantial delay in joint replacement with an artificial joint, let alone preventing it, is not possible. Summary of the Invention
[0007] The object of the present invention is to provide an implant for the replacement and regeneration of biological tissue in the form of a plug with improved load distribution and cartilage regeneration properties. Another goal is to provide such a plug-shaped implant for the replacement and regeneration of osteochondral structures. Yet another goal is to provide a method for the preparation of the implant. The present invention further aims to provide an implant that can repair articular cartilage lesions in a durable manner and at least postpone, and preferably prevent, joint replacement with an artificial joint.
[0008] These and other objectives are provided by a plug-shaped implant according to claim 1. The plug-shaped non-biodegradable implant comprises in particular a base section configured for anchoring in bone tissue and an upper section configured for replacing cartilage tissue of the intermediate and deep zone of the cartilage layer and for growing cartilage tissue on and into it, thus regenerating the superficial zone of the cartilage layer, the upper section comprising a porous thermoplastic elastomer material, the thermoplastic elastomer material comprising a linear block copolymer comprising urethane and / or urea groups, and the base section material comprising one of biocompatible metals, ceramics, minerals such as phosphate minerals, and polymers, optionally hydrogel polymers, and combinations thereof.
[0009] In cartilage, a relatively thin superficial (tangential) zone protects the deeper layers from shear stresses and accounts for approximately 10%-20% of the articular cartilage thickness. The collagen fibers in this zone (mainly collagen types II and IX) are tightly packed and aligned parallel to the articular surface (Figure 2). The superficial layer contains a relatively large number of flattened chondrocytes, and the integrity of this layer is essential for the protection and maintenance of the deeper layers. This zone, in contact with the synovial fluid, is responsible for most of the tensile properties of cartilage, which allows it to resist the shear, tensile, and compressive forces exerted by the joint.
[0010] Immediately beneath or deep to the superficial zone is the central (intermediate or transitional) zone, which provides an anatomical and functional bridge between the superficial and deep zones. The central zone represents 40%-60% of the total cartilage volume and contains proteoglycans and thicker collagen fibrils. In this layer, the collagen is organized obliquely and the chondrocytes are globular and of low density. Functionally, the central zone is the first line of resistance to compressive forces.
[0011] Considering that collagen fibrils are arranged perpendicular to the articular surface, the deep zone of cartilage is responsible for providing the greatest resistance to compressive forces. The deep zone contains the largest diameter collagen fibrils in radial alignment, the highest proteoglycan content, and the lowest water concentration. Chondrocytes are typically arranged in a columnar orientation, parallel to the collagen fibers and perpendicular to the joint line. The deep zone represents approximately 30% of the articular cartilage volume.
[0012] The porous upper section of the non-biodegradable implant of the present invention replaces at least the central and deep zones of cartilage.
[0013] Preferably, the thermoplastic elastomer material is substantially free of further peptide compounds having cartilage regenerating properties. Even more preferably, the thermoplastic elastomer material is substantially free of any further compounds having cartilage regenerating properties.
[0014] The base section material can be made of any suitable material that provides an adequate level of mechanical support to the surrounding bone and preferably allows bone formation. Suitable materials, including the thermoplastic elastomer material of the upper section of the implant, are biocompatible, meaning that they can coexist with biological tissues or organisms without harming them. Furthermore, the implant according to the present invention is substantially non-biodegradable, combining cartilage replacement with cartilage regeneration. By non-biodegradable material in the context of the present invention is meant a material that is not degraded by the environment of the implant into less complex compounds or compounds with fewer carbon atoms. The weight average molecular weight of the substantially non-biodegradable material is reduced by at most 20%, more preferably at most 10%, even more preferably at most 5%, and even more preferably at most 1% relative to the original weight average molecular weight after one year of implantation.
[0015] Suitable metals for the base section material include, but are not limited to, titanium, zirconium, chromium, aluminum, stainless steel, hafnium, tantalum, or molybdenum, and alloys thereof, or any combination thereof. Optionally, a surface layer of the metal may be oxidized, nitrided, carburized, or boronized to form a coated metal base section.
[0016] Suitable ceramics and minerals for the base section material include, but are not limited to, oxides, nitrides, carbides, or borides, or any combination thereof. Suitable examples include bioactive glasses, calcium phosphates such as beta-tricalcium phosphate (TCP), biphasic calcium phosphate, and apatites such as hydroxyapatite, fluoroapatite, chlorapatite, and / or calcium deficient apatite, and combinations thereof.
[0017] Suitable (hydrogel) polymers as base section materials include, but are not limited to, collagen, poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polycaprolactone (PCL), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), polyacrylamide, polyurethane, polyethylene glycol (PEG), chitin, poly(hydroxyalkyl methacrylate), water-swellable N-vinyl lactams, starch graft copolymers, and derivatives and combinations thereof.
[0018] Other preferred materials for the base section include polyaryletherketone (PAEK) polymers. PAEK polymers include semi-crystalline thermoplastic polymers containing alternating ketone (R-CO-R) and ether groups (ROR). The linking group R between the functional groups includes 1,4-substituted aryl groups. PAEK polymers used in the base section may include, among others, PEK (polyetheretherketone), PEEK (polyetheretherketone), PEKK (polyetherketoneketone), PEEKK (polyetheretherketoneketone), and PEKEKK (polyetherketoneetherketoneketone). Due to its excellent resistance to hydrolysis, the polyaryletherketone polymer of the base section is advantageously used in the invented implant. The polyaryletherketone polymer does not degrade when sterilized or when implanted in the body for a long time. It has also been found that the polyaryletherketone polymer bonds particularly well to the elastomeric material of the top section.
[0019] The materials used within the base region of the invented implant may be used as such or, in one embodiment, may include reinforcing materials selected from the group consisting of fibrous or particulate polymers and / or metals.
[0020] The base section of the invented implant may also include a radiation absorbing medical imaging contrast agent such as a radiocontrast agent or an MRI contrast agent, or a radiopharmaceutical that itself emits radiation, etc. The base section may also include small solid objects or solids such as beads that may include, for example, a refractory metal such as tantalum.
[0021] The base section of the plug-shaped implant serves as a bone anchor, whereas the top section serves as a partial replacement for damaged cartilage and as a scaffold for cartilage regeneration. In a plug-shaped implant, the top section refers to the section closest to the cartilage phase when implanted. The base section refers to the section furthest from the cartilage phase when implanted.
[0022] The cross section of the plug-shaped implant through a horizontal or vertical plane may have any suitable shape. The cross section may be circular, rectangular, or polygonal, such as hexagonal, octagonal, or decagonal. In some embodiments, the plug-shaped implant may be tapered, so as to be shaped as a truncated cone structure. Preferably, the implant has a smaller cross section at the base section than at the top section. The cross section (or diameter in the case of a cylindrical implant) may vary continuously between the base section and the top section, or may show discontinuities, for example at the interface between the sections.
[0023] When the implant has a tapered profile, the angle of the tapered portion is preferably 1°-45°. In some embodiments, the tapered portion is about 3°-30°, more preferably 5°-30°, even more preferably 10°-15°. The tapered profile can facilitate the insertion of the implant into the osteochondral defect and can further reduce possible damage to the host tissue. The implant is preferably used without any attachment means, remaining in the osteochondral structure by its shape and the surrounding tissue structure. The implant can be used in the knee, but also in other joints such as the temporomandibular joint, the ankle, the hip joint, the shoulder, etc.
[0024] According to the present invention, the plug-shaped implant comprises an upper section above a base section, which has a dual function of acting to replace cartilage tissue and being configured to allow cartilage tissue to grow on and into it. The thermoplastic elastomer material of the upper section is porous and comprises a linear block copolymer comprising urethane and / or urea groups. Moreover, in one embodiment, the thermoplastic elastomer material is substantially free of additional peptide compounds having cartilage regeneration properties. Surprisingly, it has been found that the implant of the present invention regenerates cartilage tissue and thus makes it possible to avoid the use of any functional compound exhibiting cartilage regeneration properties. In particular, it has been found that the implant according to this embodiment does not require the use of peptides, such as those comprising the RGD sequence. These compounds are said to enable integrin binding and thereby stimulate cell adhesion.
[0025] The linear block copolymers of the present invention are segmented copolymers with elastic properties resulting from hydrogen bonding interactions between the molecular chains. Such copolymers may contain "hard" crystallized blocks of polyurethane and / or polyurea segments with "hard" crystallized blocks of polyester and / or polyamide between the "soft" blocks. At room temperature, the low melting "soft" blocks may be incompatible with the high melting "hard" blocks, which induces phase separation by crystallization or liquid-liquid separation. These copolymers exhibit reversible physical crosslinks resulting from the crystallization of the "hard" blocks of the segmented copolymers. Thermoplastic elastomers can be formed into any shape at higher temperatures, more particularly at temperatures above the melting point of the "hard" blocks. Thermoplastic elastomers, on the other hand, provide mechanical stability and elastic properties at low temperatures, i.e., typical body temperatures. This makes these materials particularly suitable as replacement materials for human or animal cartilage.
[0026] The thermoplastic elastomer building blocks may generally include three building blocks: a long-chain diol, for example with a polyether, polyester, or polycarbonate backbone, a difunctional diisocyanate, and finally a chain extender such as water, another (sometimes short-chain) diol, or a diamine. The latter chain extenders are preferred because they introduce bis-urea units into the thermoplastic elastomer.
[0027] Preferred are embodiments of the implant in which the thermoplastic elastomer material is aliphatic. This means that all building blocks of the thermoplastic elastomer are devoid of aromatic groups and contain only aliphatic groups. The thermoplastic elastomer of the present invention can be prepared in a one-pot procedure in which a long-chain diol is first reacted with an excess of diisocyanate to form an isocyanate-functionalized prepolymer. The isocyanate-functionalized prepolymer is then reacted with a chain extender, such as a preferred diamine, resulting in the formation of a high molecular weight thermoplastic elastomer polymer containing urethane groups. When a diamine is used as a chain extender, the thermoplastic elastomer also contains bis-urea groups, which is preferred.
[0028] The synthetic procedures for preparing thermoplastic elastomers can lead to a distribution in the "hard" block length. As a result, the phase separation of these block copolymers may be incomplete in that some of the "hard" blocks, especially the shorter blocks, dissolve in the soft phase, causing an increase in the glass transition temperature. This is less desirable for the low-temperature flexibility and elasticity of the thermoplastic elastomer material in the upper section. Polydispersity in the "hard" blocks shows up as a broad melting range and a temperature-dependent rubbery plateau in dynamic mechanical thermal analysis (DMTA). Thus, preferred embodiments include elastomeric block copolymers containing "hard" blocks of substantially uniform length. These can be prepared by fractionation of a mixture of "hard" block oligomers and subsequent copolymerization of uniform "hard" block oligomers of a specific length (or length variation) with the prepolymers described above.
[0029] Thermoplastic elastomers can be prepared by chain extension of isocyanate-functionalized prepolymers with diamines, but also by chain extension of amine-functionalized prepolymers with diisocyanates. Examples of suitable commercially available diamines and diisocyanates include alkylenediamines and / or diisocyanates, arylenediamines and / or diisocyanates. Amine-functionalized prepolymers are also commercially available or can be prepared from (readily available) hydroxy-functionalized prepolymers by cyanoethylation followed by reduction of the cyano group, Gabriel synthesis (halogenation or tosylation followed by modification with phthalimide and finally deprotection of the phthalimide group to form a primary amine), or other methods known in the art. Isocyanate-functionalized prepolymers can be prepared by reaction of hydroxy-functionalized prepolymers with diisocyanates such as isophorone diisocyanate (IPDI), 1,4-diisocyanatobutane, 1,6-diisocyanatohexane, or 4,4'-methylenebis(phenylisocyanate). Alternatively, isocyanate-functionalized prepolymers can be prepared from amine-functionalized prepolymers, for example, by reaction with di-tert-butyl tricarbonate. Hydroxy-functionalized prepolymers of any kind of composition, typically with molecular weights ranging from about 500 g / mol to about 5000 g / mol, are also advantageously used. Examples include prepolymers of polyethylene glycol, polypropylene glycol, poly(ethylene-co-propylene) glycol, and polyethers such as poly(tetrahydrofuran), polyesters such as poly(caprolactone) or polyadipates, polycarbonates, polyolefins, hydrogenated polyolefins such as poly(ethylene-butylene). Polycarbonates are preferred.
[0030] Particularly preferred are polycarbonate prepolymers. Such prepolymers produce implants according to an embodiment in which the thermoplastic elastomer material further comprises carbonate groups in addition to urethane and / or urea groups. Such implants have proven to meet the objectives of the present invention better than other implants. In particular, they have proven to be beneficial in that their mechanical properties are well matched to those of human or animal cartilage. Surprisingly, when using this embodiment in implanted implants, cartilage regeneration is improved.
[0031] A particularly preferred embodiment of the present invention provides an implant, wherein the thermoplastic elastomeric material comprises poly-urethane-bisurea-alkylene carbonate, more preferably poly-urethane-bisurea-hexylene carbonate.
[0032] Apart from preferably excluding peptide compounds with cartilage regenerating properties, and in other embodiments excluding any compounds with cartilage regenerating properties in the linear block copolymer, the implant may include agents in the implant or patch composition and / or agents that facilitate the migration, integration, regeneration, proliferation, and growth of cells in and around the injury or defect, and / or promote the healing of the injury or defect, and / or agents that promote chondrogenesis and osteogenesis, i.e., building, growing, and producing cartilage and bone, respectively. These agents include, but are not limited to, cytokine compounds, chemokine compounds, chemoattractant compounds, antimicrobial compounds, antiviral compounds, anti-inflammatory compounds, proinflammatory compounds, bone or cartilage regenerating molecules, cells, blood components (e.g., whole blood and platelets), and combinations thereof. Agents that enhance strength and facilitate attachment may also be included in the implant.
[0033] The thermoplastic elastomer material of the upper section is porous. The porous material includes pores, which are defined as tiny openings. The pores may be micropores with a diameter of less than 1 mm, or macropores with a diameter of more than 1 mm. The pores may be interconnected, which is preferred, meaning that they are internally connected or that there is continuity between parts or elements. A non-porous material in the context of the present invention does not mean a material that is impermeable to molecules of any size, although some small molecules may actually be able to pass through the non-porous material. Rather, a non-porous material in the context of the present invention refers to a material that is impermeable to synovial fluid and / or blood. By substantially non-porous material in the context of the present invention, we mean a material that has a porosity of less than 20% relative to the total volume of the material, preferably at most 10%, more preferably at most 5%, and even more preferably at most 1% of the total volume of the material.
[0034] The pore size within the porous portion of the implant may be selected from 100 to 1000 microns, more preferably from 100 to 500 microns, and most preferably from 300 to 500 microns.
[0035] The thermoplastic elastomers used in the upper section of the implant are particularly advantageous since they can adapt their mechanical properties to those of human and animal cartilage. In an embodiment of the invention, an implant may be provided in which the porous elastomer material of the upper section has an elastic modulus at room temperature of less than 8 MPa, more preferably less than 6 MPa, less than 5 MPa, less than 4 MPa, less than 3 MPa, less than 2 MPa, and most preferably less than 1 MPa.
[0036] In the context of the present application, room temperature means a temperature in the range of 20-30°C, more preferably 25°C.
[0037] Embodiments with the above disclosed favorable mechanical properties of the upper section tend to promote cartilage regeneration, which is believed to be due to favorable stress (re)distribution in the osteochondral structure containing the implant during (dynamic) loading.
[0038] The modulus of elasticity may be affected by modifying the porosity of the material in the upper region, or by modifying the physical properties of the material in the upper region, for example through changing its weight average molecular weight.
[0039] The average porosity of the elastomeric material of the upper section can be chosen within wide limits. A preferred average porosity of the elastomeric material of the upper section is selected from 20-80% by volume, more preferably 30-70% by volume, even more preferably 40-60% by volume, and most preferably 45-55% by volume. The porosity of the elastomeric material in the upper section can be substantially the same across the upper section. Alternatively, the porosity of the elastomeric material in the upper section can vary across the upper section. The porosity of the elastomeric material in the upper section can vary in the lateral direction of the plug-shaped implant and / or in the longitudinal direction of the plug-shaped implant. A preferred embodiment relates to an implant, in which the porosity of the elastomeric material in the upper section increases in the lateral direction of the plug-shaped implant from a low value at the center of the plug-shaped implant towards a higher value at the outside of the implant. In another preferred embodiment, the porosity of the elastomeric material in the upper section increases in the longitudinal direction of the plug-shaped implant from a low value at the lower surface of the upper section towards a higher value at the upper surface of the upper section. The low porosity value may be selected, for example, from 20 to 45 vol%, more preferably from 25 to 45 vol%, even more preferably from 30 to 45 vol%, and most preferably from 35 to 45 vol%. The high porosity value may be selected, for example, from 45 to 70 vol%, more preferably from 45 to 65 vol%, even more preferably from 45 to 60 vol%, and most preferably from 45 to 55 vol%.
[0040] In the implant according to the invention, the base section is in direct contact with the porous top section. Useful embodiments of the invention provide implants in which the base section comprises a core of non-porous base section material and a shell, preferably a periphery, of porous base section material, the shell having a thickness that is less than 10% of the maximum diameter of the base section. Other useful embodiments provide implants in which the (peripheral) shell has a thickness that is less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of the maximum diameter of the base section. Alternatively, the cross-sectional area of the (peripheral) shell covers at most 35% of the maximum cross-sectional area of the base section. Other useful embodiments provide implants in which the cross-sectional area of the (peripheral) shell is less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 3%, or less than 1% of the maximum cross-sectional area of the base section.
[0041] Another embodiment of the present invention provides an implant in which the base section extends between the upper and lower surfaces and includes a layer of porous base section material, the layer adjacent the upper surface and having a thickness that is less than 10% of the maximum height of the base section, and the pores of the base section material in the layer include a biocompatible elastomeric material, preferably all pores. In other embodiments, the layer adjacent the upper surface has a thickness that is less than 10%, less than 8%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of the maximum height of the base section. All of the above embodiments can improve the adhesion of the top section to the base section to various degrees. At the same time, the mechanical properties of the base section and the support provided by the base section to the implant remain at a suitable level.
[0042] Another embodiment of the present invention relates to an implant comprising a substantially non-porous polyaryletherketone polymer having a porosity of less than 20% relative to the total volume of the polyaryletherketone polymer.
[0043] Yet another embodiment provides an implant, wherein the base section comprises a non-porous polyaryletherketone polymer.
[0044] In another embodiment of the invention, the top surface of the base section of the implant comprises irregularities or undulations. The irregularities may include, for example, protrusions having a sawtooth shape. The undulations may be irregular or regular, such as having a sinusoidal shape.
[0045] Another useful embodiment relates to an implant in which the base section includes a centrally located cavity that contains a biocompatible elastomeric material. Such a cavity can further improve the adhesion of the top section to the base section. The cavity can be cylindrical, or its cross section can be rectangular or polygonal. The walls of the cavity can also be uneven or undulating, or include areas of cross-sectional area larger than its average cross-sectional area. Several of such cavity areas can be provided at different heights of the base section to form a mechanical locking structure.
[0046] Yet another embodiment provides an implant in which the base section includes an outer surface having irregularities or undulations. Such outer surface irregularities may include, for example, protrusions having a sawtooth shape, extending circumferentially over (a part of) the outer surface of the base section. The undulations may be irregular or regular, such as having a sinusoidal shape. The undulations may also extend circumferentially over (a part of) the outer surface of the base section. The irregularities and undulations may be provided by pouring material into a mold of suitable shape, or may be provided by machining, for example by turning a molded implant.
[0047] The height of the plug-shaped implant can be chosen according to the specific application in the body. The height can vary, for example, from 3 to 18 mm. According to a useful embodiment of the present invention, an implant is provided in which the height of the base section and the height of the porous top section are chosen so that the top surface of the implant is below the top surface of the cartilage present on the osteochondral structure when implanted, preferably at a distance of 0.1 to 1 mm. This embodiment encourages the cartilage tissue to grow not only in but also on the top section, thereby building a strong anchorage between the top section and the newly formed cartilage. It has been found that chondrocytes from the host cartilage have a strong affinity for the segmented elastomer of the top section and are therefore prone to settle on its surface and generate new hyaline cartilage tissue on top of the implant.
[0048] Another embodiment provides an implant in which the height of the base section and the height of the porous upper section are selected so that the underside of the upper section is approximately at the same level as the underside of the cartilage present on the osteochondral structure when implanted.
[0049] Yet another embodiment of the present invention provides an upper surface section, the upper surface of which is slightly curved. The preferred radius of curvature of the upper surface of the upper surface section in the sagittal plane is selected in the range of 15-150 mm, more preferably 17-125 mm, even more preferably 19-100 mm, even more preferably 21-75 mm, even more preferably 23-50 mm, and most preferably 25-30 mm. This embodiment allows for a new cartilage layer to be regenerated on the upper surface of the upper surface section of the implant with a thickness that is approximately equal across the upper surface. The result may be a radius of the upper surface of the regenerated cartilage that is approximately the same as the radius of the surrounding natural cartilage layer next to the implant, thereby showing a continuity of radii. The upper surface of the upper section of the implant may also be curved with a radius of curvature in the medial-lateral plane, preferably having the range disclosed above for the sagittal plane. In a practical embodiment, the upper surface of the upper section of the implant has equal radii of curvature in the sagittal and medial-lateral planes. This embodiment therefore includes a spherical upper surface.
[0050] Another aspect of the present invention provides a method for the preparation of an implant, comprising the steps of: a) providing in a mold at room temperature a base section comprising a base section material comprising one of a biocompatible metal, a ceramic, a mineral such as a phosphate mineral, and a polymer, optionally a hydrogel polymer, and combinations thereof, and on the base section, grains of a thermoplastic elastomeric material, wherein the thermoplastic material comprises a linear block copolymer comprising urethane and urea groups; b) closing the mould and heating the above assembly to a temperature of 100°C to 250°C under a pressure of 1 to 2 GPa such that the thermoplastic elastomer material melts and fuses with the base section; c) cooling the assembly to room temperature to solidify the thermoplastic elastomer material and opening the mold; and d) providing pores in the upper region of the thermoplastic elastomeric material either before or after opening the mould.
[0051] A preferred embodiment provides a method wherein step a) comprises providing a base section material comprising a substantially non-porous polyaryletherketone polymer having a porosity of less than 20% relative to the total volume of the polyaryletherketone polymer in the mould at room temperature.
[0052] A preferred embodiment provides a method, wherein the thermoplastic elastomer material is substantially free of further peptide compounds having cartilage regenerating properties, and even more preferably free of any compounds having cartilage regenerating properties.
[0053] Another embodiment of the invention provides a method, in which after step b), the mould is opened and additional granules of thermoplastic elastomer material are added to the mould and step b) is repeated. The amount of material added in the two-step embodiment of the method can be chosen within wide limits. Increasingly better results are obtained when the ratio between the first and second addition of granules of thermoplastic elastomer material is selected from 01:99 to 99:01, more preferably 30:70 to 97:03 and most preferably 70:30 to 95:05.
[0054] Another embodiment of the present invention provides a process, wherein the heating temperature in step b) is between 110° C. and 225° C., more preferably between 120° C. and 200° C., and most preferably between 130° C. and 175° C. The preferred pressure in all the cited temperature ranges is between 1.1 and 1.8 GPa, and more preferably between 1.2 and 1.6 GPa.
[0055] Yet another aspect of the present invention relates to a method for the preparation of a thermoplastic elastomer material comprising a linear block copolymer comprising urethane and urea groups and substantially free of further peptide compounds having cartilage regenerating properties, the method comprising the steps of: - preparing an isocyanate-terminated prepolymer by reacting a diol with a diisocyanate; - polymerizing an isocyanate-terminated prepolymer by chain extension with a diamine, The above steps are carried out in the absence of peptide compounds having cartilage regenerative properties.
[0056] Preferably, the above method for the preparation of a thermoplastic elastomer material is carried out with the exclusion of any compound having cartilage regenerative properties.
[0057] In a preferred process according to one embodiment, the diol is selected from polyester diols, polyether diols, and preferably carbonate diols, and combinations thereof.
[0058] Another preferred embodiment provides a method wherein the diisocyanate comprises an n-alkylene-diisocyanate.
[0059] Yet another preferred embodiment of the present invention relates to a process, wherein the diamine comprises a primary diamine, preferably an n-alkylene-diamine. [Brief description of the drawings]
[0060] The invention will now be further clarified by the following figures and examples, without however being limited thereto. In the figures: [Figure 1A-1D] 1A-1D show schematic side views of four embodiments of exemplary implants according to the present invention. [Figure 2A] 2 shows a schematic perspective view of a base section according to one embodiment of the present invention. [Figure 2B] FIG. 2B shows a schematic cross-sectional view of the embodiment of FIG. 2A. [Fig. 2C-2D] 2C shows a schematic detail view of parts B and C of the embodiment of FIG. 2B. [Diagram 3] FIG. 1 shows a schematic diagram of a possible synthetic route to a thermoplastic polycarbonate material according to an embodiment of the present invention. [Figure 4] 1 shows a 1H-NMR spectrum of a thermoplastic polycarbonate material according to an embodiment of the present invention. [Figure 5A-5C] 1 shows DSC thermograms of a thermoplastic polycarbonate material according to an embodiment of the present invention at different heating rates. [Figure 6A-6C] 6A-6C show schematic diagrams of a defect in an osteochondral structure (6A), an osteochondral structure including an implant according to an embodiment of the present invention (6B), and the same osteochondral structure after cartilage over-growth / ingrowth (6C). [Figure 7A-7D] 1 shows schematic side views of four embodiments of an implant according to yet another embodiment of the invention; [Figure 8A-8C] 8A-8C show schematic diagrams of a defect in an osteochondral structure (8A), an osteochondral structure including an implant according to another embodiment of the invention (8B), and the same osteochondral structure after cartilage over-growth / ingrowth (8C).
[0061] Referring to FIG. 1A, a side view of an exemplary embodiment of an implant according to the present invention is shown. The implant 1, in the form of a plug, comprises a base section 2 configured for anchoring in bone tissue and a porous top section 4 configured for replacing cartilage tissue and for cartilage tissue to grow on and into it. The top section 4 comprises a thermoplastic elastomer material in porous form. The thermoplastic elastomer material in this embodiment comprises poly-urethane-bisurea-hexylene carbonate, the preparation and properties of which will be further clarified below. The base section 2 comprises a non-porous polyaryletherketone polymer, which in the embodiment shown is a non-porous PEKK polymer. The implant 1 is cylindrical and has a diameter 10 of 6 mm. The height 20 of the base section 2 and the height 40 of the top section 4 add up to a total height of 6 mm.
[0062] FIG. 1B shows a schematic side view of another embodiment of an implant according to the invention. The implant 1, again embodied in the form of a plug, comprises a base section 2 configured for anchoring in bone tissue and an upper section 4 configured for replacing cartilage tissue and for growing cartilage tissue on and into it. The upper section 4 comprises the same porous poly-urethane-bis-urea-hexyl carbonate material. The base section 2 comprises a substantially non-porous PEKK polymer having a porosity of less than 20% relative to the total volume of the PEKK polymer. The base section 2 in this embodiment comprises in particular a core 21 of non-porous PEKK polymer and a peripheral shell 22 of porous PEKK polymer. The shell 22 has a thickness 23 of about 8% of the diameter 10 of the base section 2 (and of the implant 1). The base section 2 further extends between the upper surface 24 and the lower surface 25 and includes a layer 26 of porous PEKK polymer adjacent the upper surface 24 and having a thickness 27 of about 8% of the height 20 of the base section 2. The pores of the PEKK polymer in the layer 26 originate from the top section 4 and include biocompatible poly-urethane-bisurea-hexylene carbonate that has infiltrated the pores of the PEKK polymer in the layer 26 during manufacture. The method for manufacturing the implant will become more clear below. As with the embodiment of FIG. 1A, the implant 1 is cylindrical and has a diameter 10 of 6 mm. The height 20 of the base section 2 and the height 40 of the top section 4 add up to a total height of 6 mm.
[0063] FIG. 1C shows a schematic side view of yet another embodiment of an implant according to the invention. The implant 1, again embodied in the form of a plug, comprises a base section 2 configured for anchoring in bone tissue and an upper section 4 configured for replacing and growing on and into cartilage tissue. The upper section 4 comprises a poly-urethane-bisurea-hexylene carbonate material that is porous in the upper section 4. The base section 2 comprises a substantially non-porous PEKK polymer having a porosity of less than 20% with respect to the total volume of the PEKK polymer. The base section 2 of this embodiment in particular extends between the upper face 24 and the lower face 25 and comprises a layer 26 of porous PEKK polymer, which layer 26 is adjacent to the upper face 24 and has a thickness 27 of about 8% of the height 20 of the base section 2. The pores of the PEKK polymer in the layer 26 originate from the upper section 4 and comprise biocompatible poly-urethane-bisurea-hexylene carbonate that has infiltrated the pores of the PEKK polymer in the layer 26 during manufacture. The dimensions and shape are the same as the embodiment of Figures 1A and 1B.
[0064] FIG. 1D shows a schematic side view of yet another embodiment of an implant according to the invention. The embodied implant 1 in the form of a plug corresponds to that shown in FIG. 1C. In addition, the porosity of the elastomeric material in the upper section 4Ap increases in the transverse direction 30 of the plug-shaped implant 1 from a low value of about 35% by volume at the center line 3 of the plug-shaped implant to a higher value of about 55% by volume at the outer side of the implant 1. Furthermore, the porosity of the elastomeric material in the upper section 4 increases in the longitudinal direction 31 of the plug-shaped implant 1 from a low value of about 35% by volume at the lower surface of the upper section 4 (corresponding to the upper surface 24 of the base section 2) to a higher value of about 55% by volume at the upper surface 41 of the upper section 4. Furthermore, the base section 2 comprises a layer 26 of porous PEKK polymer, adjacent to the upper surface 24 and having a thickness 27 of about 5% of the height 20 of the base section 2. The pores of the PEKK polymer in layer 26 originate from top section 4 and include biocompatible poly-urethane-bisurea-hexylene carbonate that has infiltrated the pores of the PEKK polymer in layer 26 during manufacture. Base section 2 further includes a core 21 of non-porous PEKK polymer, and a peripheral shell 22 of porous PEKK polymer. Shell 22 has a thickness 23 of approximately 5% of the diameter 10 of base section 2 (and implant 1). Finally, base section 2 also includes a layer 28 of porous PEKK polymer adjacent lower surface 25 and having a thickness 29 of approximately 5% of the height 20 of base section 2. The dimensions and shape are the same as the embodiment of Figures 1A-1C.
[0065] 1B, 1C, and 1D, the peripheral shells (22, 32) are shown in cross section to show their respective thicknesses (23, 33). In side view, the peripheral shells (22, 32) extend across the entire diameter 10 of the implant 1.
[0066] Referring to Figure 7A, a side view of another embodiment of an implant according to the invention is shown. The implant 1 in the form of a plug comprises the same materials and regions as shown in Figure 1A. The dimensions of the implant in Figure 7A are the same as those of the implant in Figure 1A, with one exception. Instead of having a flat upper surface 41 of the upper section 4 (and thus of the implant 1) as in Figure 1A, the upper surface 41a of the upper section 4 is spherical with a radius of curvature R of about 28 mm (not drawn to scale).
[0067] With reference to FIG. 7B, a side view of another embodiment of an implant according to the invention is shown. The implant 1 in the form of a plug comprises the same materials and areas as shown in FIG. 1B. The dimensions of the implant in FIG. 7B are the same as those of the implant in FIG. 1B, with one exception. Instead of having a flat upper surface 41 of the upper section 4, as in FIG. 1B, the upper surface 41a of the upper section 4 is spherical with a radius of curvature R of about 28 mm (not drawn to scale). With reference to FIG. 7C, a side view of another embodiment of an implant according to the invention is shown. The implant 1 in the form of a plug comprises the same materials and areas as shown in FIG. 1C. The dimensions of the implant in FIG. 7C are the same as those of the implant in FIG. 1C, with one exception. Instead of having a flat upper surface 41 of the upper section 4, as in FIG. 1C, the upper surface 41a of the upper section 4 is spherical with a radius of curvature R of about 28 mm (not drawn to scale).
[0068] Referring to Figure 7D, a side view of another embodiment of an implant according to the invention is shown. The implant 1 in the form of a plug comprises the same materials and sections as shown in Figure 1D. The dimensions of the implant in Figure 7D are the same as those of the implant in Figure 1D, with one exception. Instead of having a flat upper surface 41 of the upper section 4 as in Figure 1D, the upper surface 41a of the upper section 4 is spherical with a radius of curvature R of about 28 mm (not drawn to scale).
[0069] Again, note that in Figures 7B, 7C, and 7D, the peripheral shells (22, 32) are shown in cross section to show their respective thicknesses (23, 33). In side view, the peripheral shells (22, 32) extend across the entire diameter 10 of the implant 1 (not drawn to scale).
[0070] 2A-2D, an embodiment of the base section 2 of the invented implant 1 is shown in a schematic manner. The base section 2 shown is essentially cylindrical with a diameter 10 and a height 20. The top surface 24 of the base section has a peripheral flat edge portion 240 that gradually extends into a centrally located cavity 241. The cavity 241 is provided with a locking portion 242 having a diameter larger than the diameter of the cavity 241. As shown in detail in FIG. 2C, the locking portion 242 of the cavity 241 is disc-shaped, whereby the outer edge of the disc forms an angle 246 of 1°-20°, more preferably 5°-15°, with the longitudinal direction 247 of the base section 2. The cavity 241 (and portion 242) during the manufacture of the implant is filled with a portion of a biocompatible elastomeric material to provide a suitable locking of the top section 4 to the base section 2. As noted above, the base section 2 comprises a PEKK polymer that may be non-porous or substantially non-porous, and embodiments of the PEKK polymer that may be substantially non-porous include the examples disclosed above. The base section 2 further appears to include an uneven or undulating outer surface. In this embodiment, these include peripheral projections 243 that, in cross section, are sawtooth shaped, as shown in detail in FIG. 2D. The angle 244 at which the sawtooth flanks extend relative to the transverse direction 245 of the base section 2 is preferably between 70° and 85°, more preferably between 75° and 80°.
[0071] Preparation of the elastomeric material of the upper section Example 1: Polycarbonate-Aliphatic: Poly(hexylene carbonate urethane)-bis-urea biomaterial MVH313, see Table 1 below.
[0072] This one-pot, two-step generated biomaterial, MVH313, was prepared by functionalization of 1.0 molar equivalent of poly(hexylene carbonate) diol (MW = 2000) with 2.0 molar equivalent of 1,6-diisocyanatohexane (step 1) and subsequent chain extension using 1.0 molar equivalent of 1,6-diaminohexane (step 2).
[0073] In particular, the aliphatic poly-urethane-urea-hexylene carbonate biomaterial of the top section 4 was prepared as follows (see FIG. 3). Poly(hexylene carbonate) diol (MW=2000; 23.9 g, 11.9 mmol) was weighed into a 500 mL 3-neck flask and dried by heating to 75° C. overnight under vacuum and then cooled to room temperature. Under an argon atmosphere, 1,6-diisocyanatohexane (4.1 g, 23.9 mmol), DMAc (20 mL), and one drop of Sn(II) bis(2-ethylhexanoate) were added, after which the mixture was heated and stirred for 3 hours to increase the viscosity. The mixture was cooled to room temperature, diluted with DMAc (100 mL), and a solution of 1,6-diaminohexane (1.4 g, 11.9 mmol) in DMAc (50 mL) was added in one portion under thorough mixing. Upon addition and mixing, a gel was formed immediately. The mixture was further diluted with DMAc (150 mL) and heated in an oil bath at 130° C. to obtain a homogeneous, viscous slurry. After cooling to room temperature, the mixture was precipitated in a water / brine mixture (2.75 L water + 0.25 L saturated brine) to obtain a soft white material. This material was cut into smaller pieces and stirred in a 1:5 mixture of methanol and water (3 L) for 64 h. After decanting the supernatant, the resulting solid was stirred in a 2:1 mixture of methanol and water (0.75 L) for 6 h. The supernatant was decanted and stirred in a 2:1 mixture of methanol and water (0.75 L) for 16 h, the supernatant was decanted, and the solid was dried in vacuum at 70° C. to obtain a flexible, tough, elastomeric polymer.
[0074] The resulting polymers were analyzed using a Varian 200, Varian 400 MHz, or 400 MHz Bruker spectrometer at 298 K. 1H NMR spectroscopy was performed. DSC was performed using a Q2000 machine (TA Instruments). Heating scan rates of 10° C. / min and 40° C. / min were used for evaluation of melting temperature (Tm) and glass transition temperature (Tg), respectively. Tm was determined by the peak melting temperature and Tg was determined from the inflection point.
[0075] All reagents, chemicals, materials, and solvents were obtained from commercial sources and used without further purification. The poly(hexylene carbonate) diol used had an average molecular weight of about 2 kg / mol. Figures 4 and 5 show the results of the polymerization of the resulting polymer, respectively. 1 The H NMR spectrum and DSC thermogram are shown. 1 The results of the H NMR spectra can be summarized as follows: 1 H NMR (400 MHz, HFIP-d2): δ = 4.23 (m, n*4H, n ~ 14.3), 4.10 (m, 4H), 3.17 (m, 12H), 1.87-1.32 (multiple signals for aliphatic CH2 methylene) ppm. The average molecular weight of the repeating hard / soft block segments is ~2.5 kDa. The DSC results can be summarized as follows: DSC (10 °C / min, Figure 5A): Tm (top) = 20.9 °C (soft block melt); DSC (40 °C / min, Figure 5B): Tg = -38.0 °C. No second melting point for the hard block was observed up to 200 °C. However, in the final heating run to 250 °C at 10 °C / min (Figure 5C), a small and broad melting transition was observed at ~227 °C. On a DSC diagram, the endothermic melting peak plots downwards whereas the exothermic crystallization peak plots upwards.
[0076] The non-porous aliphatic poly-urethane-urea-hexylene carbonate biomaterial had an elastic modulus of 3.6±0.03 MPa according to ASTM D638.
[0077] Example 2: Polyether-aromatic: poly(tetrahydrofuran urethane)-bis-urea biomaterial MVH309B, see Table 1 below.
[0078] Biomaterial MVH309B was also produced in a one-pot, two-step experimental procedure similar to that detailed for Biomaterial MVH313. In particular, Biomaterial MVH309B was prepared by functionalization of 1.0 molar equivalent of poly-tetrahydrofuran diol (MW=2000) with 1.33 molar equivalent of bis(4-isocyanatophenyl)methane (MDI) (step 1) and subsequent chain extension using 0.33 molar equivalent of 1,6-diaminohexane (step 2). Biomaterial MVH309B was isolated as a white, flexible, tough, elastomeric polymer.
[0079] Example 3: Polyether-Aliphatic: Poly(tetrahydrofuranurethane)-bis-urea biomaterial MVH312, see Table 1 below.
[0080] Biomaterial MVH312 was also produced in a one-pot, two-step experimental procedure similar to that detailed for Biomaterial MVH313. In particular, Biomaterial MVH312 was prepared by functionalization of 1.0 molar equivalent of poly-tetrahydrofuran diol (MW=2000) with 2.0 molar equivalent of 1,6-diisocyanatohexane (step 1) and subsequent chain extension using 1.0 molar equivalent of 1,6-diaminohexane (step 2). Biomaterial MVH312 was isolated as a flexible, tough, elastomeric polymer.
[0081] Example 4: Polycarbonate-aromatic: Poly(hexylene carbonate urethane)-bis-urea biomaterial MVH311, see Table 1 below.
[0082] Biomaterial MVH311 was also produced in a one-pot, two-step experimental procedure similar to that detailed for Biomaterial MVH313. In particular, Biomaterial MVH311 was prepared by functionalization of 1.0 molar equivalent of poly(hexylene carbonate) diol (MW=2000) with 1.33 molar equivalent of bis(4-isocyanatophenyl)methane (MDI) (step 1) and subsequent chain extension using 0.33 molar equivalent of 1,6-diaminohexane (step 2). Biomaterial MVH311 was isolated as a flexible, tough, elastomeric polymer.
[0083] Mechanical properties of the elastomeric material in the non-porous upper section Stress relaxation tests were performed on the two aromatic and two aliphatic polymers of Examples 1-4, as well as on three equine cartilage specimens obtained from Utrecht Medical Centre. A description of the specimens (e.g., polymer class) and their dimensions are listed in Table 1. Using an Instron Electropulse E10000, each specimen was compressed to a strain of 0.05 mm / mm at a strain rate of 0.005 s-1, which was held constant for 1800 seconds. All tests were performed in triplicate. Load, displacement, and time were recorded during the tests, and stress relaxation curves were then obtained from the data. Stress relaxation is illustrated by determining the stress relaxation rate G(t) at the start of stress relaxation (G(0)) and 1800 seconds after the start of stress relaxation (G(1800)) using the following formula: G(t)=σ(t) / ε0, where σ(t) is the compressive stress and ε0 is the set (constant) strain. [Table 1] The results are shown in Table 2 below. [Table 2]
[0084] Preparation of biomaterial-covered PEKK bone anchors The implant 1 was produced by attaching a top section 4 to a PEKK base section 2, which acts as a bone anchor. In a method according to an embodiment of the invention, the PEKK bone anchor was covered with a poly-urethane-urea-hexylene carbonate biomaterial by pressing small granules of an aliphatic polycarbonate polymer onto and into the PEKK anchor. A custom-made pressing device was used for this purpose. Various temperatures (100°C to about 150°C), compression forces (2 kN to about 4 kN), and methods were tested. The best results were obtained using a two-step procedure employing a temperature of 150°C and using a compression force of 40 kN (4 tons, or 4000 kg; corresponding to a pressure of 1.4 GPa). Temperatures below 150° C. appeared to give a less homogeneously pressed poly-urethane-urea-hexylene carbonate biomaterial layer (zones 3 and 4), while higher temperatures were less desirable since they may degrade the urea groups in the poly-urethane-urea-hexylene carbonate biomaterial to some extent. In a first step, about 50 mg of polymer 12 was pressed onto and into the PEKK bone anchor for 15 minutes, while in a second step, about 2 mg of polymer 12 was added to the device and the sample was pressed under the same conditions (150° C. and 40 kN) for another 15 minutes. The sample was then removed from the compression device and then cooled. After the second pressing step, the surface of the poly-urethane-urea-hexylene carbonate biomaterial layer (zones 3 and 4) on the base zone 2 appeared to be substantially flat. The biomaterial was nearly transparent and colorless. The edges of the biomaterial showed some tufts or frays which were removed using a scalpel.
[0085] The central hole (241, 242) in the base section 2 was approximately 4.5 mm deep and 2 mm in diameter. The hole was substantially filled with the poly-urethane-urea-hexylene carbonate biomaterial, and the attachment of the biomaterial to the PEKK base section 2 appeared to be quite strong and robust. It proved virtually impossible to remove the biomaterial from the PEKK base section by force or to loosen the connection at the PEKK-biomaterial interface. All used instruments and accessories intended to come into contact with the PEKK base section 2 and / or the elastomeric biomaterial were rinsed with ethanol or isopropanol and then dried. After pressing and cutting any fraying, the PEKK-biomaterial plug implant was rinsed with isopropanol and dried. Plugs can also be produced in a sterile environment, if necessary.
[0086] As assessed by measurements, the PEKK base section was 6 mm in diameter and 6 mm high (6 mm tall). The central cavity within the base section was approximately 2 mm in diameter and 4.5 mm deep. The elastomeric biomaterial (aliphatic polycarbonate) positioned over the PEKK base section was approximately 6 mm in diameter and 1 mm tall. Thus, the entire PEKK-biomaterial plug implant was approximately 7 mm tall.
[0087] The upper section 4 was porosified by drilling holes therein with an average diameter of 300 microns until the final porosity was 50% by volume. The porous aliphatic poly-urethane-urea-hexylene carbonate biomaterial of the upper section 4 had an elastic modulus of 0.9±0.2 MPa according to ASTM D638.
[0088] The implant 1 can be implanted into an osteochondral defect 8, as shown in Figures 6A-6C. In a typical method, the cartilage defect extending into the subchondral bone (Figure 6A) is drilled out and the plug-shaped implant 1 is implanted into the drilled hole under some pressure ("press-fit"), as shown in Figure 6B. Bone then grows onto, and in some embodiments into, the PEKK base section 2, which anchors the implant 1. As shown in Figure 6C, the surrounding natural cartilage 5 grows onto the upper side 41 of the top section 4, and new cartilage 5a is created on top of the implant 1. As also shown in Figure 6C, the height 20 of the base section 2 and the height 40 of the porous top section 4 are selected so that the top surface 41 of the implant 1 is at a distance 51, preferably 0.1-1 mm, below the top surface 50 of the cartilage 5 present on the osteochondral structure (5, 6) when implanted. In the present case, this distance was about 0.5 mm. The osteochondral structure (5, 6) comprises the subchondral bone 6 and a cartilage layer 5 above it. A synovial cavity 7 is also typically present.
[0089] As also shown in Figures 6B and 6C, the height 20 of the base section 2 and the height 40 of the porous upper section 4 are selected so that the lower surface 24 of the upper section 4 (or the upper surface 24 of the base section 2) is approximately at the same level as the lower surface 51 of the cartilage layer 5 of the osteochondral structure (5, 6) when implanted.
[0090] Finally, the implant according to the embodiment shown in Figures 7A-7D can also be implanted in an osteochondral defect 8, as shown in Figures 8A-8C. Due to the spherical upper surface 41a of the top layer 4, this embodiment can regenerate a new cartilage layer 5a on the upper surface 41a of the upper surface section 4 of the implant 1 with an approximately equal thickness across the upper surface 41a. The result can be a radius of the upper surface 50 of the regenerated cartilage 5a that is approximately the same as the radius of the surrounding natural cartilage layer 5 next to the implant, thereby showing a continuity of the radius.
[0091] Preparation of metallic bone anchors covered with biomaterial Another embodiment of the implant 1 was produced by attaching the upper section 4 to a titanium base section 2, which acts as a bone anchor. The titanium used was the alloy Ti6A14V, which is readily commercially available. The titanium base section was provided with pores with an average pore size of about 300 microns. In a method according to an embodiment of the invention, the titanium bone anchor was covered with a poly-urethane-urea-hexylene carbonate biomaterial by pressing small grains of an aliphatic polycarbonate polymer onto and into the pores of the titanium anchor. For this purpose, the same custom-made pressing device was used as in the previous example. Optimal results were again obtained using a two-step procedure employing a temperature of 150° C. and a compression force of 40 kN (4 tonnes, or 4000 kg; corresponding to a pressure of 1.4 GPa). In a first step, about 50 mg of elastomeric polymer was pressed onto and into the titanium bone anchor for 15 minutes, while in a second step, about 2 mg of elastomeric polymer was added to the device and the sample was pressed under the same conditions (150° C. and 40 kN) for another 15 minutes. The sample was then removed from the compression device and then cooled. After the second pressing step, the surface of the poly-urethane-urea-hexylene carbonate biomaterial layer (zones 3 and 4) on top of base section 2 appeared substantially flat. The biomaterial was nearly transparent and colorless. Some edges of the biomaterial showed tufts or fraying, which were removed using a scalpel.
[0092] Like the PEKK proximal anchor, the titanium proximal anchor was provided with a central hole (241, 242) having the same dimensions. The hole was substantially filled with the poly-urethane-urea-hexylene carbonate biomaterial, and attachment of the biomaterial to the titanium proximal section 2 was satisfactory.
[0093] The titanium base section 2 had the same dimensions as the PEKK base section. Because the same mold was used, the elastomeric biomaterial (aliphatic polycarbonate) positioned on the titanium base section was approximately 6 mm in diameter and 1 mm in height. Thus, the entire titanium-biomaterial plug implant was approximately 7 mm high.
[0094] The upper section 4 was porosified by drilling holes therein with an average diameter of 300 microns until the final porosity was 50% by volume. The porous aliphatic poly-urethane-urea-hexylene carbonate biomaterial of the upper section 4 had an elastic modulus of 0.9±0.2 MPa according to ASTM D638.
[0095] As already mentioned above, the implant 1 can be implanted in an osteochondral defect 8, as shown in Figures 6A-6C. In a typical method, the cartilage defect extending into the subchondral bone (Figure 6A) is drilled out and a plug-shaped implant 1 is implanted in the drilled hole, as shown in Figure 6B. Due to the relatively high stiffness of the titanium base section 2, a press-fit is not appropriate. Instead, the dimensions of the drilled out subchondral bone were slightly larger than the dimensions of the titanium base section 2. The bone appears to grow onto the titanium base section 2, which anchors the implant 1. As shown in Figure 6C, the surrounding natural cartilage 5 grows onto the upper side 41 of the top section 4, and new cartilage 5a is created on top of the implant 1. As also shown in Figure 6C, the height 20 of the base section 2, and the height 40 of the porous top section 4 are selected such that the upper surface 41 of the implant 1 is below the upper surface 50 of the cartilage 5 present on the osteochondral structure (5, 6) when implanted, preferably at a distance 51 of 0.1-1 mm. In the present case, this distance was about 0.5 mm. The osteochondral structure (5, 6) comprises a subchondral bone 6 and an overlying cartilage layer 5. A synovial cavity 7 is also typically present.
[0096] As also shown in Figures 6B and 6C, the height 20 of the base section 2 and the height 40 of the porous upper section 4 are selected so that the lower surface 24 of the upper section 4 (or the upper surface 24 of the base section 2) is approximately at the same level as the lower surface 51 of the cartilage layer 5 of the osteochondral structure (5, 6) when implanted.
[0097] Many variations and applications of the invention within the scope of the appended claims will be apparent to those skilled in the art.
Claims
1. A non-biodegradable implant for the replacement and regeneration of biological tissue, in the form of a plug, comprising a base section adapted for fixing in bone tissue and an upper section adapted for replacing the cartilage tissue of the intermediate and deep zones of the cartilage layer and for growing cartilage tissue onto and into it, thus regenerating the superficial zone of said cartilage layer, the top section comprises a porous thermoplastic elastomeric material; the thermoplastic elastomeric material comprises a linear block copolymer containing urethane and urea groups; The base section material comprises one of the following: (I) to (V): (I) a biocompatible metal; (II) ceramic; (III) minerals; (IV) polymer; (V) A combination of (I) to (IV) the thermoplastic elastomer material further comprises a carbonate group; The polymer of (IV) is a (hydrogel) polymer selected from collagen, poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polycaprolactone (PCL), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), polyacrylamide, polyurethane, polyethylene glycol (PEG), chitin, poly(hydroxyalkyl methacrylate), water-swellable N-vinyl lactam, starch graft copolymer, and derivatives and combinations thereof, or the polymer of (IV) is a non-hydrogel polyaryletherketone polymer. Implant.
2. The implant of claim 1 , wherein the thermoplastic elastomer material is substantially free of additional peptide compounds having cartilage regenerating properties.
3. The implant of claim 1 or claim 2, wherein the thermoplastic elastomer material comprises a poly-urethane-bis-urea-alkylene carbonate.
4. The implant of any one of claims 1 to 3, wherein the thermoplastic elastomer material is aliphatic.
5. An implant according to any one of claims 1 to 4, wherein the porous thermoplastic elastomeric material has a modulus of elasticity at room temperature of less than 8 MPa.
6. 6. The implant of any one of claims 1 to 5, wherein the base section comprises a core of non-porous base section material and a peripheral shell of porous base section material, the shell having a thickness that is less than 10% of the maximum diameter of the base section.
7. 7. The implant of any one of claims 1 to 6, wherein the base section extends between an upper surface and a lower surface and comprises a layer of porous base section material, the layer adjacent the upper surface and having a thickness that is less than 10% of a maximum height of the base section, and pores of the base section material in the layer comprise a biocompatible elastomeric material.
8. 8. The implant of any one of claims 1 to 7, wherein the material of the base section comprises a metal selected from titanium, zirconium, chromium, aluminum, stainless steel, hafnium, tantalum, or molybdenum, and alloys thereof, or any combination thereof.
9. The implant of any one of claims 1 to 8, wherein the material of the base section comprises a ceramic or mineral selected from oxides, nitrides, carbides, and borides, or any combination thereof.
10. 10. The implant of claim 1 comprising a substantially non-porous polyaryletherketone polymer having a porosity of less than 20% based on the total volume of the polyaryletherketone polymer.
11. The implant of claim 1 or 2, wherein the base section comprises a non-porous polyaryletherketone polymer.
12. An implant as claimed in any one of claims 1 to 11, further comprising a contrast agent or radiopharmaceutical for medical imaging, or a body.
13. The implant of any one of claims 1 to 12, wherein the upper surface of the base section comprises irregularities or undulations.
14. The implant of any one of claims 1 to 13, wherein the base section includes a centrally located cavity containing the elastomeric material.
15. The implant of any one of claims 1 to 14, wherein the base section comprises a rough or contoured outer surface.
16. 16. The implant of any one of claims 1 to 15, wherein the height of the base section and the height of the porous upper section are selected such that the upper surface of the implant is below the upper surface of the cartilage that will reside on the osteochondral structure when implanted.
17. 17. The implant according to any one of claims 1 to 16, wherein the height of the base section and the height of the porous upper section are selected such that the lower surface of the upper section is approximately at the same level as the lower surface of the cartilage present on the osteochondral structure when implanted.
18. An implant according to any one of claims 1 to 17, comprising an upper section having a slightly curved upper surface with a radius of curvature in the sagittal and / or medial-lateral plane in the range of 15mm to 150mm.
19. An implant according to any one of claims 1 to 18, wherein the material of the base section comprises a reinforcing material selected from the group consisting of fibrous or particulate polymers and / or metals.
20. A method for the preparation of an implant according to any one of claims 1 to 19, comprising the steps of: a) providing in a mould at room temperature a base section comprising a base section material and on said base section grains of thermoplastic elastomer material, The base section material comprises one of the following: (I) to (V): (I) a biocompatible metal; (II) ceramic; (III) minerals; (IV) polymer; (V) A combination of (I) to (IV) the thermoplastic elastomeric material comprises a linear block copolymer containing urethane and urea groups, and carbonate groups; The polymer of (IV) is a (hydrogel) polymer selected from collagen, poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polycaprolactone (PCL), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), polyacrylamide, polyurethane, polyethylene glycol (PEG), chitin, poly(hydroxyalkyl methacrylate), water-swellable N-vinyl lactam, starch graft copolymer, and derivatives and combinations thereof, or the polymer of (IV) is a non-hydrogel polyaryletherketone polymer. Step a, b) closing the mold and heating the above assembly to a temperature of 100° C. to 250° C. under a pressure of 1 to 2 GPa such that the thermoplastic elastomer material melts and fuses with the base section; c) cooling the assembly to room temperature to solidify the thermoplastic elastomer material and opening the mold; d) providing pores in an upper region of said thermoplastic elastomeric material either before or after opening the mold.
21. 21. The method of claim 20, wherein the thermoplastic elastomer material is substantially free of additional peptide compounds having cartilage regenerative properties.
22. 22. The method of claim 20 or 21, wherein after step b), the mould is opened, additional granules of the thermoplastic elastomeric material are added to the mould and step b) is repeated.
23. 20. An osteochondral structure comprising an implant according to any one of claims 1 to 19, wherein a top surface of the implant is below a top surface of a cartilage layer on the osteochondral structure.
Citation Information
Patent Citations
Scaffold fixation device and method of making it
JP2003024340A
Preparation, Characterization, Reinforcement of High Performance Reticulated Elastomeric Matrices and Use in Surgical Devices, Tissue Augmentation and / or Tissue Repair
JP2009540923A
Hydrophilic interpenetrating polymer network derived from hydrophobic polymers
JP2011527377A
Polyurethane-grafted hydrogel
JP2011530336A
Porous non-biodegradable hydrogel admixed with a chemoattractant for tissue replacement
US20090017096A1
